Trial Profile
DOLOMITE NEAT ID Network Study: A Prospective, Multi-site Observational Study to Define the Safety and Effectiveness of Dolutegravir Use in HIV Positive Pregnant Women
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ViiV Healthcare
- 10 Nov 2023 Planned End Date changed from 28 Apr 2023 to 30 Sep 2024.
- 10 Nov 2023 Planned primary completion date changed from 28 Apr 2023 to 30 Sep 2024.
- 01 Jul 2022 Planned primary completion date changed from 17 Sep 2021 to 28 Apr 2023.